We found a marked variation in BCL-2 oncoprotein expreslevels were not associated with slow early response, failure sion levels of primary leukemic cells from 338 children with to achieve complete remission, or poor event-free survival. newly diagnosed acute lymphoblastic leukemia (ALL). None High BCL-2 levels in primary leukemic cells predicted slow of the high-risk features predictive of poor treatment outearly response only in T-lineage ALL patients, which comcome in childhood ALL, such as older age, high white blood prised approximately 15% of the total patient population. cell (WBC) count, organomegaly, T-lineage immunophenoEven for this small subset of patients, the level of BCL-2 type, ability of leukemic cells to cause overt leukemia in expression did not have a significant impact on the shortsevere combined immunodeficient (SCID) mice, presence of term event-free survival. MLL-AF4, and BCR-ABL fusion transcripts were associated ᭧ 1997 by The American Society of Hematology. with high levels of BCL-2 expression. Overall, high BCL-2 as being in the standard risk category if age at diagnosis is 1 to 9 B years and the WBC is less than 50,000/mL. Poor risk patients include CL-2 PROTEIN PROMOTES cell survival by preventing apoptosis.
B
years and the WBC is less than 50,000/mL. Poor risk patients include CL-2 PROTEIN PROMOTES cell survival by preventing apoptosis. [1] [2] [3] [4] [5] [6] [7] Several studies indicate that the those who are diagnosed at an age of 10 years or greater and/or who protein expression levels of BCL-2 determine the in vitro had an initial WBC equal to or greater than 50,000/mL. Patient sensitivity of lymphoma and leukemia cells to chemotheracharacteristics are detailed in dren's Cancer Group (CCG) study was to examine the BCL- fluorescence and flow cytometry using monoclonal antibodies reactive with the following lymphoid differentiation antigens CD1, CD2, MATERIALS AND METHODS CD3, CD4, CD5, CD7, CD8, CD9, CD10, CD19, CD20, CD21, CD22, CD24, and CD40, as previously described. 19, [29] [30] [31] [32] [33] [34] [35] Cases were Study patients. Three hundred and thirty eight children with newly diagnosed ALL greater than 1 year of age (ie, noninfants) who were enrolled in three risk-adjusted CCG treatment studies (ie, CCG-1922 to the amount of BCL-2 protein present in each NALM-6 cell. Leukemic cells are examined for the presence of MLL-AF-4, E2A-PBX-1 and BCR-ABL by RT-PCR, as described in Materials and Methof t(9;22)-specific BCR-ABL, t(1;19)-specific E2A-PBX1, and t(4;11)-specific MLL/AF-4 fusion transcripts using a reverse-tranods.
Abbreviations: BM, bone marrow; WBC, white blood count; BM scriptase (RT) PCR assay, as previously described. [42] [43] [44] cDNA was synthesized using 20% of the total RNA sample with 100 U of status: M1, õ5% blasts; M2, 5-25% blasts; M3, ú25% blasts.
Moloney murine leukemia virus (MMLV) reverse transcriptase (GIBCO-BRL, Gaithersburg, MD) in 11 PCR buffer (50 mmol/L KCl, 10 mmol/L Tris-Cl pH 8.3, 1.5 mmol/L MgCl 2 , and 0.01% classified as B-lineage ALL if ¢30% of leukemic cells were positive for CD19 or CD24 and õ30% were positive for CD2, CD5, and (wt/vol) gelatin), 3 mg random primers (GIBCO-BRL), 2.5 mmol/L of each of the deoxyribonucleoside triphosphates (dNTPs) (Phar-CD7. 19, 30, 35 Patients were classified as T-lineage ALL if ¢30% of blasts were positive for CD2, CD5, or CD7 and õ30% were positive macia, Piscataway, NJ), 0.01 mol/L DTT, and 20 U RNasin (Promega, Madison, WI) in a total volume of 20 mL at 37ЊC for 1 hour, for CD19 or CD24.
19,29
Western blot analysis of BCL-2 protein expression in ALL cells.
as described. [42] [43] [44] The reaction mixture (Reaction mixture 1) was then denatured at 95ЊC for 5 minutes and cooled on ice. For amplification The expression levels of BCL-2 oncoprotein in whole cell lysates of primary leukemic cells were measured centrally in the Children's of the cDNA products, samples were diluted fivefold with 11 PCR buffer containing 0.075 mg of each oligonucleotide primer, 6.25% Cancer Group ALL Biology Reference Laboratory in Roseville, MN, by Western blot analysis using a monoclonal mouse antihuman BCLdimethyl sulfoxide (DMSO) and 2.5 U Amplitaq DNA Polymerase (Perkin Elmer Cetus, Norwalk, CT) (Reaction mixture 2) and 35 2 antibody (DAKO-bcl-2, Code M857, Lot 063, DAKO, Glostrup, Denmark). In brief, leukemic cells (5 1 10 6 cells/sample) were lysed cycles of amplification were performed with a DNA thermal cycler, as reported. [42] [43] [44] Primers used were as follows: 5 TCCGAGGCCin 150 mL sodium dodecyl sulfate (SDS) lysis buffer (50 mmol/ L Tris-HCl, pH 6.8, 2% SDS, 10% glycerol, 100 mmol/L sodium ACCATCGTGGGCGTCCGC-3 and 5-TGTGATTATAGCCTA-AGACCCGGAG-3 for BCR/ABL; 5-GCCAGCCAGGCACCCorthovanadate, 25 mmol/L DTT) and boiled for 5 minutes. The DNA was sheared by several passages through a 28-gauge needle, and 40 TCCC-3 and 5-GTTGTCCAGCCGCATCAGCT-3 for E2A/ PBX1, and 5-AGAGCAGAGCAAACAGAA-3 and 5-GCTGAGmL amounts of the whole cell lysate protein samples in SDS-reducing sample buffer were fractionated on reducing SDS-polyacrylamide AATTTGAGTGAG-3 for MLL/AF-4. RNA integrity was analyzed on every sample using an ABL RT-PCR with primers 5-TTCAGCgels by overnight electrophoresis at 4 mA. The proteins were transferred to a 0.45-mm Immobilon-polyvinylidene difluoride (PVDF)
GGCCAGTAGCATCTGACTT-3 and 5-TGTGATTATAGCCTA-AGACCCGGAG-3. PCR products were then separated by electromembrane (Millipore Corp, Bedford, MA) for 1 hour at 130 mA using a semidry transfer apparatus (Hoefer Scientific Instruments, phoresis in a 1.2% agarose gel, transferred to nylon membranes by the method of Southern, and hybridized with previously reported San Francisco, CA). The PVDF membranes were incubated for 1 hour at room temperature in blocking solution (10 mmol/L Trisoligonucleotide probes, which were 5 end-labeled with g 32 P-adeno-AID Blood 0038 / 5H35$$$741 04-12-97 10:27:55 bldas WBS: Blood sine triphosphate (ATP) (ICN Pharmaceuticals, Plainview, NY) and cells were also correlated on a continuous scale with numerical variables (eg, age, WBC, day 7 bone marrow blast percentage). T4 Polynucleotide Kinase (Promega), as described. [42] [43] [44] Autoradiography was performed with Kodak XAR-5 film. Controls included Event-free survival (EFS) was defined as the time from study entry to the first major event (failure to achieve remission, relapse at any PCR reaction products of RNA-free reaction mixture 1 plus reaction mixture 2 (Å Negative control [1]), RNA-free reaction mixture 2 site, death, or second malignancy). For patients who did not experience an event, EFS was defined as the time to last follow-up and (ÅNegative control [2]), as well as PCR products from RNA samples of two ALL patients with known absence of BCR-ABL, E2A-PBX1, treated as a censored life /L exhibited signifiTherefore, we examined whether primary leukemic cells that caused leukemia in SCID mice had higher levels of BCL-2 cantly higher BCL-2 levels than did leukemic cells from patients with WBC ¢ 50 1 10 9 /L (71.6 { 2.8 U/cell v 57.7 than leukemic cells that did not grow in SCID mice. Contrary to our initial expectations, leukemic cells that caused leuke-{ 4.3 U/cell, P Å .008). Leukemic cells from patients with standard risk ALL according to the NCI Risk Criteria 45 had mia in SCID mice had significantly lower amounts of BCL-2 protein than leukemic cells that did not grow in SCID significantly higher BCL-2 levels than those from poor risk ALL patients (71.7 { 3.2 U/blast v 62.4 { 3.6, P Å .053; mice (57.4 { 5.4 U/cell v 70.1 { 2.7 U/cell, P Å .035) ( Table 2) . Table 2 ). Leukemic cells from patients who presented with splenomegaly or hepatomegaly expressed significantly lower Early response to therapy, which refers to the degree of disease regression before day 28 of induction therapy (viz., levels of BCL-2 than cells from patients without organomegaly ( Table 2 ). The presence of E2A-PBX1 fusion transcript, the time at which bone marrow remission is conventionally documented) is a highly significant and independent progwhich has been correlated with poor risk features, 45 was also associated with lower levels of BCL-2 protein (P Å .022).
nostic factor in childhood ALL. Table 2 , leukemic cells from patients with SER did not express higher levels of BCL-2 than did leukemic cells from patients with rapid early response (RER; defined as M1 or M2 marrow status on day 7) (SER v RER: 66.9 { 4.9 v 68.1 { 2.8). Similarly, patients who failed to achieve a CR by day 28 did not express high levels of BCL-2. Patients whose leukemic cell BCL-2 content was ¢65 U/ cell (Åmedian value, see Table 2 ), did not appear to have a worse EFS outcome within the first 2 years of study entry than patients whose leukemic cell BCL-2 content was õ65 U/cell (Fig 2) .
When we examined the potential role of BCL-2 expression level in predicting early response to therapy in T-lineage ALL patients separately, we found that leukemic cells from patients with SER had significantly higher BCL-2 levels than those from patients with RER (61.9 { 12.7 v 32.8 { 4.8, P ( Fig 4A) . In contrast, there was no significant correlation between BCL-2 levels and the percentages of residual leukemic cells in day 7 bone marrow samples of B-lineage ALL 53 Variable levels of BCL-2 protein are expressed in acute myeloid leukemia (AML) cells. 58, 59 Inhibition of BCL-2 protein expression by bcl-2 antisense oligodeoxynucleotides decreased the life span of AML cells in vitro and augmented their sensitivity to chemotherapeutic agents. 60 In one study, high BCL-2 expression levels were correlated with autocrine granulocyte-macrophage colony-stimulating factor (GM-CSF) production, which has been associated with poor treatment outcome. 59 High expression levels of BCL-2 were recently reported to be associated with poor prognostic features and a poor treatment outcome in AML.
2,58,61 BCL-2 expression in ALL cells has been investigated in a number of studies.
2,12,13,15,17 In one study, the expression levels of BCL-2 protein in primary leukemic cells from ALL patients correlated with their ability to survive in vitro in the absence of stromal support. 12 In other studies, a human ALL cell line transfected with bcl-2 gene exhibited significantly prolonged survival and reduced apoptosis in the pres- patients (coefficient of correlation Å 0.003, P Å .960; Fig  4B) and no differences in BCL-2 expression were discernible between the SER versus RER groups in this subset (Table  2, Fig 3) . The level of BCL-2 expression did not have a significant impact on the short-term (ie, within the first 2 years after diagnosis) EFS outcome of T-lineage ALL or Blineage ALL patients (Fig 5) .
DISCUSSION
BCL-2 is expressed at high levels in non-Hodgkin's lymphoma (NHL), especially in follicular lymphoma and impedes apoptosis mediated by several agents. 53, 54 Antisense-mediated downregulation of BCL-2 protein expression in NHL cell lines results in reduced clonogenicity 55 and enhanced sensitivity to anticancer drugs. 56 Furthermore, antisense oligonucleotides to the bcl-2 gene effectively sup- In the present analysis of 338 children with newly diagmeyer SJ: Bcl-2 is an inner mitochondrial membrane protein that nosed ALL, we found a profound interpatient heterogeneity blocks programmed cell death. Nature 348: 334, 1990 in cellular expression levels of BCL-2 oncoprotein. Overall, 
